Merrimack Pharmaceuticals reported $770K in Current Liabilities for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Bioline Rx BLRX:US $ 10.31M 0.4M
Brainstorm Cell Therapeutics BCLI:US $ 5.85M 2.21M
Celldex Therapeutics CLDX:US $ 14.18M 0.31M
Cerulean Pharma CERU:US $ 15.91M 9.9M
Clovis Oncology CLVS:US $ 112.69M 61.19M
Eleven Biotherapeutics EBIO:US $ 12.59M 6.23M
Immunogen IMGN:US $ 111.78M 8.53M
Merrimack Pharmaceuticals MACK:US $ 770K 1.45M
Newlink Genetics NLNK:US $ 6.05M 0.72M
YTE INCY:US $ 742.71M 82.39M